Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Building a Maintainable Closet: Individual Excursions in Moral Style - 2Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors
- 3When faith comes under fire: How Iran’s repression of religious minorities has increased
- 4I decided to become a single mother by choice. I wasn't ready to stop dating.
- 5Amy Poehler's podcast is a hit. It's also a Trojan horse for talking about women and aging.
- International issues on the agenda as Frances's Macron visits China
- Multi-million-euro win in Spanish lottery in doubt due to oversight
- IDF struck Iran's largest petrochemical plant, second facility hit in two days, Katz confirms
- Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
- Famous SUVs With Low Energy Utilization In 2024
- Thermo Fisher wins contracts as pharma shifts production to US, CEO says
- When the moon hits your eye from your Orion ship up high, that's a 'mare'
- Incredible Travel Objections for Craftsmanship Darlings to Visit
- the Kinds of Thailand: Decision in favor of Your Number one Thai Dish!
